Number	Title	Revision Log
NH.PMN.92	CNS Stimulants	Removed redirection to brand name Daytrana due to the state removal from the brand preferred strategy list
NH.PHAR.285	Nintedanib (Ofev)	Added example of positive response to therapy to continuation criteria
NH.PHAR.206	Carglumic Acid (Carbaglu)	Added clinical documentation requirement to initial criteria and example of responding positively to therapy in continuation criteria
NH.PHAR.169	Vigabatrin (Sabril, Vigafyde)	Added clinical documentation requirement to initial criteria and requirement for ophthalmology testing around treatment
NH.PHAR.200	Hepatitis C Agents	Added clinical documentation requirement for multiple criteria and added prescriber specialty or training
NH.PHAR.296	Pegfilgrastim and Biosimilars	Added requirement to document neutropenic fever risk along with risk factors
NH.PHAR.603	Exagamglogene Autotemcel (Casgevy)	Added clinical documentation requirement to multiple criteria and changed 8 transfusions to 10 to align with other criteria within policy
NH.PMN.50	Anti-Obesity Medications	Added requirement for submission of weight and BMI and no utilization of multiple weight loss medications concurrently
NH.PMN.97	Opioid Analgesics	Added prescriber specialist requirements and timeline around PDMP checks and review of pain treatment plan
NH.PHAR.427	Siponimod (Mayzent)	Added clinical documentation requirement to both initial and continuation criteria. Added EDSS score requirement.
NH.PHAR.237	Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit)	Added clinical documentation requirements, minimum hematocrit values
NH.PMN.110	Crisaborole (Eucrisa)	Added additional continuation criteria for positive therapy and re-evaluation
NH.PMN.124	Itraconazole (Sporanox, Tolsura)	Added additional criteria to onychomychosis diagnosis along with requirement for clinical documentation to support multiple criteria
NH.PHAR.261	Secukinumab (Cosentyx)	Added clinical documentation requirement for trial and failures. Added criteria for Hidradenitis Suppurativa. Increased duration of approval to 12 months for chronic conditions
NH.PHAR.462	Ozanimod (Zeposia)	Added clinical documentation requirement for initial criteria and EDSS Score requirement
NH.PHAR.256	Interferon Beta-1b (Betaseron, Extavia)	Added clinical documentation requirement for initial and continued criteria. Added EDSS requirements
NH.PMN.48	Cyclosporine (Cequa, Verkazia, Vevye, Klarity-C, Restasis)	Added clinical documentation requirements, prescriber requirements, 30-day trial requirements
NH.PHAR.255	Interferon Beta-1a (Avonex, Rebif)	Added clinical documentation required for multiple criteria and added EDSS score requirements
NH.PMN.199	Esketamine (Spravato)	Added additional criteria around REMS, duration of trial and failures, and concomitant use of medications. Additional details were added requiring clinical documentation. Added MDD criteria around psychosis risk.